Deals wrap: Vaccine makers all the rage

September 17, 2010

A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado April 14, 2009. REUTERS/Rick WilkingJohnson & Johnson, looking to catapult itself into the global vaccine market, is in talks to pay $2.3 billion to buy Dutch biotech Crucell. The potential deal may be more proof it was a question of not if, but rather when other successful biotech companies with late-stage products will be bought. The potential deal also signals that J&J is most likely out of that race for Genzyme.

“The bid price on the remaining shares can be considered as a knock-out price and is substantially higher than the analysts’ consensus target price,” one analyst said. *View article*

Speaking of Genzyme, one of the keys to a successful bid for the biotech company may lie with the heavyweights on the board of Sanofi. The French based pharmaceutical group, which has just lost its flamboyant, long-standing chairman, is dominated by representatives of top shareholders Total and L’Oreal , but is also brimming with pharma experts brought in via acquisitions.

“What’s unusual is the way Sanofi has been cobbled together,” said a teacher from the French business school INSEAD.

Any hopes from Genzyme shareholders for a dramatically improved bid may hinge on how the internal dynamics of this disparate board play out. *View article*

Denmark’s telecom operator TDC agreed to sell its Swiss unit Sunrise for $3.3 billion in a deal seen by analysts as readying TDC for a stock offering.

“I see a reintroduction on the stock market of all shares as the most likely way for the current owners to exit, and they have now cleared the last hurdle for that as they now have a focus on the Nordic region only,” one analyst said. *View article*

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see